A gelatin-binding 95000-M, protein was detected in human serum and plasma by immunoblotting using antibodies against the 95000-Mr gelatin-binding protein, a major secretory component of cultured adherent human monocyte/macrophages. Serum and plasma were prepared by incubating blood at 4, 22 or 37°C for different periods of time, and gelatin-binding proteins were isolated from 200 1 portions by gelatin-Sepharose affinity chromatography. The bound material was analysed by sodium dodecyl sulphate/polyacrylamide-gel electrophoresis. In protein-stained gels, fibronectin and some minor polypeptides were seen, but not the 95 000-Mr protein. In immunoblotting of identical serum samples the antibodies detected apparently two closely spaced polypeptide bands at M, 95 000, and in plasma samples a single band at the position of the faster-migrating one of the two above-mentioned bands. The immunoperoxidase reaction was stronger when serum and plasma were prepared by incubating for longer periods of time (up to 8 h) or at higher temperatures (up to 37°C). In samples made from plasma, the immunoperoxidase reactions were weaker than in those from serum, indicating a lower quantity of the protein. The results suggest that the 95 000-M, protein is released from monocytes and granulocytes during the
the 95 000-M, protein is released from monocytes and granulocytes during the incubation of blood and, more likely, when they possibly interact with the blood clot and may become adherent.
Human monocyte/macrophages produce an exceptionally large variety of substances involved in the host defence systems, e.g. in inflammatory conditions (Nathan et al., 1980; Lasser, 1983) . These include, among others, complement components, proteolytic enzymes and both activators and inhibitors of proteinases. In a previous study we have shown that cultured adherent human macrophages and U-937 pro-monocytic cells produce as their major secretory component a 95000-Mr gelatin-binding protein (Vartio et al., 1982a,b) , which was also found in blood granulocytes, but not in any other cell type in blood (Vartio et al., 1985) . This protein had no immunological crossreactivity with other gelatin-binding proteins produced by cultured cells, namely fibronectin and a 70000-Mr polypeptide (Vartio & Vaheri, 1981; Vartio et al., 1982a,b) .
The present study describes the detection of a 95 000-Mr gelatin-binding protein in human serum and plasma by using immunoblotting and anti- Tubes with or without sodium citrate were then incubated at 4, 22 or 37°C for 2, 4, 6 or 8 h. After incubation the tubes were centrifuged at 1200 rev./min (r 15cm) for 10min to isolate serum and plasma from blood cells.
Affinity chromatogrpahy
Serum and plasma samples (200 or 400 p1) were treated with 80p1 of 50% (v/v) gelatin-Sepharose in NaCl/Pi, incubated in an end-over rotator for 2 h, washed with NaCl/P, and mixed with 40pl of Vol. 228 T. Vartio Laemmli's (1970) sample buffer to analyse the bound proteins by SDS/polyacrylamide-gel electrophoresis (see below). Before gelatin-Sepharose chromatography, the serum and plasma samples were treated with unsubstituted Sepharose 4B to remove most of the non-specifically binding proteins. In control experiments unsubstituted Sepharose 4B was used instead of gelatinSepharose.
SDS/polyacrylamide-gel electrophoresis
This was performed as described by Laemmli (1970) , with vertical slab gels. The acrylamide concentration was 3.3% in the spacer gel and 6% in the separating gel. The samples were reduced with 10% (v/v) 2-mercaptoethanol in Laemmli's (1970) sample buffer. After electrophoresis, the gels were either stained with Coomassie Brilliant Blue or used in immunoblotting (see below). Commercially obtained Mr markers (Pharmacia, Uppsala, Sweden) were used.
Results
Detection of the 95000SMr protein in serum and plasma Human serum and plasma from the same blood sample were prepared by incubating blood, with or without sodium citrate as an anticoagulant, at different temperatures (4, 22 and 37°C) for 2, 4, 6 or 8 h. The gelatin-binding proteins from the resulting serum and plasma were then isolated and analysed by SDS/polyacrylamide-gel electrophoresis as described in the Materials and methods section. Fig. 1 shows SDS/polyacrylamide-gel electrophoresis of the gelatin-binding proteins from 200 pl of serum and plasma prepared by incubating blood at 37°C for 4h. In addition to fibronectin, several minor components were seen Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets Immunoblotting was performed as described by Towbin et al. (1979) . In this procedure, polypeptides separated by SDS/polyacrylamide-gel electrophoresis were transferred electrophoretically to nitrocellulose sheets (type I HAWP filter; Millipore, Bedford, MA, U.S.A.). As a modification of the original method (Towbin et al., 1979) , the transferred proteins were located by using reversible heparin/toluidine staining (Vartio et al., 1982a,b) . Other methods
Human blood monocyte/macrophages were isolated and cultured as described by Hovi et al. (1976) . The 95000-Mr protein was purified by gelatin-Sepharose chromatography from serumfree growth medium of cultured human monocyte/ macrophages and antiserum against it was prepared and characterized as described previously (Vartio et al., 1982a,b) . Granulocytes were isolated from the buffy-coat fractions of human blood as described by B0yum (1968) . The granulocytes were extracted with 0.5% Triton X-100 in 5mM-Tris/HCl, pH7.5, and the 95000Mr protein was isolated by gelatin-Sepharose chromatogrpahy as described by Vartio et al. (1985) . The Fig. 2 shows immunoblotting of identical samples with antiserum raised against the 95 000-Mr macrophage protein (tracks 1 and 2) . The immunoperoxidase reaction at the 95 000-M, position is clearly stronger in the sample made from serum than in that made from plasma. Furthermore, the immunoperoxidase reaction in the serum sample appeared as a broad zone that was apparently composed of two closely spaced bands (track 1, Fig. 2 ), whereas that in plasma sample formed only one band (tracks 2 and 3, Fig. 2 ), co-migrating with the faster one of the two bands mentioned above. This is seen more clearly in the immunoperoxidase reaction in track 3, in which the sample was made from double the amount (400 ,u) of the same plasma used in track 2. The gelatin-binding proteins from the Triton X-100 extract of human blood granulocytes (the 95000-M, protein) and from the growth medium of cultured human blood macrophages (fibronectin and the 95000-Mr protein) are shown in protein-stained tracks 4 and 5 respectively. As a control, identical samples were immunoblotted with the anti-(95000-Mr protein) serum (tracks 6 and 7 respectively).
The gelatin-binding proteins from serum and plasma samples, prepared by incubating portions of blood at 37°C for 2, 4, 6 or 8 h, were also analysed by immunoblotting. Fig. 3 shows such an experiment performed with serum samples. It can be seen that the strength of the immunoperoxidase reaction increased as a function of time, indicating the increase in the quantity of the protein in samples prepared after longer incubations. When similar samples were made at lower temperatures (22 or 4°C) as well as from portions of plasma, the immunoperoxidase reactions were weaker or absent (results not shown).
When 3 l of total serum or plasma was electrophoresed and immunoblotted, no immunoperoxidase reaction was detected by using anti-(95 000-Mr protein) serum at the dilution of 1 :100 
Discussion
The present paper shows that a protein immunologically cross-reactive with the major secretory polypeptide produced by cultured human macrophages (Mr 95000; Vartio et al., 1982a,b) can be detected in human serum and plasma. The protein has also been detected in blood granulocytes, but not in other blood cells (Vartio et al., 1985) . The evidence presented is based on the partial purification of the protein by gelatin-Sepharose from serum and plasma and on the detection of it in immunoblotting with antibodies raised against the 95000 Mr macrophage protein.
Immunoperoxidase reaction in the gelatin-binding material at the position of 95000 Mr was stronger when serum was prepared by clot formation at 37°C than when lower temperatures were used. The reaction was also stronger the longer period of time blood had been incubated in the preparation of serum and plasma samples (Fig. 3) .
In the samples made from plasma, the reactions were weaker than in corresponding serum samples (Fig. 2, tracks 1 (Vartio et al., 1982a,b) .
However, the possibility that the protein is released as a result of cell destruction in vitro cannot totally be excluded. If this were true, it would have been expected that the immunoperoxidase reactions would have been identical in both serum and plasma samples.
In serum-derived samples the immunoperoxidase reaction formed a broad band, apparently representing a doublet of two closely spaced bands, whereas that in plasma samples was a narrow single band co-migrating with the lower band of the doublet mentioned above. The explanation could be that the 95000-M, protein in plasma was derived only from macrophages, whereas the bands detected in serum were formed from the proteins produced by both macrophages and granulocytes. This interpretation corresponds to a previous study in which the 95000-Mr protein detected in human blood granulocytes had somewhat slower electrophoretic mobility than that produced by macrophages (Vartio et al., 1985) , as shown in Fig. 2, tracks 4 and 5. Alternatively, the slower-migrating band may represent a precursor form of the 95 000-M, macrophage protein, although no such a protein has been detected in cellculture experiments (Vartio et al., 1982a,b) .
In spite of the present data obtained in vitro, it is not known whether the 95000-M protein is a normal component of blood in vivo. It may, however, be possible to detect it on occasions when granulocytes and monocytes become adherent and the proteins they secrete have access into the blood. More detailed studies are, however, needed to elucidate the appearance of the 95 OOO-Mr protein in serum and plasma, or whether the protein could also be used as a marker of certain pathological or physiological conditions, e.g. those in which blood clotting takes place.
